CRIS Current Research Information System

GANDOLFI, LETIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.649
NA - Nord America 2.353
AS - Asia 1.849
SA - Sud America 104
AF - Africa 102
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.061
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.321
NL - Olanda 1.988
SG - Singapore 562
DE - Germania 554
VN - Vietnam 520
CN - Cina 385
GB - Regno Unito 297
SE - Svezia 243
IT - Italia 151
HK - Hong Kong 134
RU - Federazione Russa 86
FR - Francia 85
BR - Brasile 81
IN - India 75
UA - Ucraina 71
IE - Irlanda 45
JP - Giappone 37
BD - Bangladesh 35
ZA - Sudafrica 35
TG - Togo 31
FI - Finlandia 28
EE - Estonia 25
KR - Corea 22
CA - Canada 19
PL - Polonia 15
BE - Belgio 11
CI - Costa d'Avorio 11
TH - Thailandia 11
AR - Argentina 10
CH - Svizzera 10
HR - Croazia 9
NG - Nigeria 9
PH - Filippine 9
BG - Bulgaria 8
MX - Messico 8
TR - Turchia 8
ID - Indonesia 7
IR - Iran 7
JO - Giordania 7
LB - Libano 7
ES - Italia 5
IQ - Iraq 5
EG - Egitto 4
TW - Taiwan 4
CL - Cile 3
EC - Ecuador 3
JM - Giamaica 3
KE - Kenya 3
LT - Lituania 3
MY - Malesia 3
TN - Tunisia 3
AT - Austria 2
DZ - Algeria 2
GR - Grecia 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
SA - Arabia Saudita 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CO - Colombia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
ME - Montenegro 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 8.061
Salva come PNG Salva come JPEG
Città #
Eygelshoven 1.285
Kerkrade 666
Singapore 392
Frankfurt am Main 361
Southend 257
Fairfield 246
Ashburn 217
Santa Clara 169
Chandler 151
Houston 135
Woodbridge 129
Hong Kong 124
San Jose 120
Seattle 112
Ann Arbor 105
Wilmington 97
Cambridge 87
Ho Chi Minh City 83
Dong Ket 67
Beijing 65
Hanoi 65
Princeton 62
Boardman 57
Dublin 45
New York 35
Kyiv 33
Los Angeles 33
Lomé 31
Nanjing 30
Berlin 29
Tokyo 28
Buffalo 27
Helsinki 27
Westminster 27
Hefei 26
Padova 26
Lauterbourg 25
Jinan 24
Falkenstein 23
Bremen 21
Bologna 19
Seoul 19
Council Bluffs 17
Jacksonville 16
São Paulo 15
Da Nang 14
Dallas 14
Secaucus 14
Dearborn 13
Shenyang 13
Changsha 12
San Diego 12
Toronto 12
Abidjan 11
Hangzhou 11
Hebei 11
Brussels 10
Chicago 10
Düsseldorf 10
Guangzhou 10
Haiphong 10
Nanchang 10
Warsaw 10
Bern 9
Milan 9
Munich 9
Redondo Beach 9
Turin 9
Abeokuta 8
Columbus 8
Jiaxing 8
Shanghai 8
The Dalles 8
Amman 7
Florence 7
Hyderabad 7
Istanbul 7
Bangkok 6
Falls Church 6
Haikou 6
London 6
Saint Petersburg 6
San Francisco 6
Tianjin 6
Zhengzhou 6
Falconara Marittima 5
Johannesburg 5
Monmouth Junction 5
Norwalk 5
Paris 5
Phoenix 5
Redwood City 5
Sofia 5
Taiyuan 5
Taizhou 5
Bengaluru 4
Brooklyn 4
Bến Tre 4
Can Tho 4
Lanzhou 4
Totale 6.066
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.851
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 256
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 250
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 240
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 223
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 217
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 206
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 205
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 197
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 195
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 183
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 181
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 180
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 175
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 171
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 170
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 168
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 165
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 162
Vemurafenib mucosal side-effect. 153
Primary ocular adnexal lymphomas: a retrospective study of 25 patients. 152
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 151
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 149
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 147
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 142
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 139
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 129
CAMPYLOBACTER PYLORI IN ABATTOIR WORKERS: IS IT A ZOONOSIS? 39
Endoscopic retrograde cholangiopancreatography (ERCP) in the elderly 37
A possible source of Campylobacter pylori? ELISA testing of abattoir workers 35
Cancer of the gastric stump in Italy, 1979–1986 34
Detection of helicobacter pylori-like organisms in the stomach of some food-source animals using a monoclonal antibody 34
Cancer of the gastric stump in Italy, 1979–1986 30
Gemcitabine 28
Detection of helicobacter pylori-like organisms in the stomach of some food-source animals using a monoclonal antibody 27
IS CAMPYLOBACTER PYLORI A ZOONOSIS? 26
The source of Campylobacter pylori 25
CAMPYLOBACTER PYLORI IN ABATTOIR WORKERS: IS IT A ZOONOSIS? 23
The source of Campylobacter pylori 20
Totale 8.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.288
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.288
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021189 0 0 0 0 0 0 0 0 0 0 0 189
2021/2022648 103 36 34 67 52 28 19 32 20 31 118 108
2022/2023687 83 110 51 93 43 65 13 45 78 20 38 48
2023/2024211 30 28 13 34 15 31 26 3 4 12 7 8
2024/2025838 22 76 33 55 206 28 105 16 10 64 23 200
2025/20264.010 91 116 139 77 242 1.395 1.209 68 426 136 81 30
Totale 8.146